阿里健康(00241.HK)推临床试验数字化管理平台「码上放心」
阿里健康(00241.HK)宣布推出「码上放心」平台,用於新药研发的临床试验药物编盲与数字化管理,帮助药企实现临床试验药物全程可追溯。
阿里健康表示,目前中国的临床试验用药还主要靠人工记录的方法进行管理,难以实现系统化管理、实时监测和全程追溯,而「码上放心」则为每一盒临床试验用药提供独一无二的20位追溯码,全程实现一药一码、来源可查、去向可追及温度可控。
目前中国已有超过98%的药品生产企业使用「码上放心」平台,平台服务已延伸到除新药临床试验外的生鲜食品追溯、跨境医药电商等多个领域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.